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Substrate scope for trimethyllysine hydroxylase
catalysis†
Abbas H. K. Al Temimi,‡ Bas J. G. E. Pieters,‡ Y. Vijayendar Reddy, Paul B. White
and Jasmin Mecinovic´*
Trimethyllysine hydroxylase (TMLH) is a non-haem Fe(II) and
2-oxoglutarate dependent oxygenase that catalyses the C-3 hydroxyl-
ation of an unactivated C–H bond in L-trimethyllysine in the first
step of carnitine biosynthesis. The examination of trimethyllysine
analogues as substrates for human TMLH reveals that the enzyme
does hydroxylate substrates other than natural L-trimethyllysine.
Carnitine (L-3-hydroxy-4-N,N,N-trimethylaminobutyrate) is an
important metabolite that plays the central role in the transport
of long chain fatty acids from cytosol to the mitochondrial
matrix in most eukaryotes and several prokaryotes.1–3 The bio-
synthetic pathway leading to carnitine involves four enzymatic
steps starting from L-trimethyllysine (TML, 1), which is derived
from the hydrolytic degradation of posttranslationally modified
trimethyllysine-containing proteins (Fig. 1).3,4 The first and
the last steps in carnitine biosynthesis are catalysed by Fe(II)
and 2-oxoglutarate (2OG) dependent oxygenases, trimethyllysine
hydroxylase (TMLH) and g-butyrobetaine hydroxylase (BBOX),
respectively (Fig. 1). Human TMLH and BBOX exhibit a relatively
high degree of homology, with several key residues conserved,
including: (i) the iron chelating triad His-Asp-His, (ii) the active
site Arg that forms a salt-bridge with the C-5 carboxylate of
the 2OG co-substrate, and (iii) the aromatic cage that consists
of Tyr and Trp, and associates with the positively charged
trimethylammonium group of trimethyllysine (for TMLH) or
g-butyrobetaine (for BBOX).5 A notable difference between these
two oxygenases includes the site that is presumably responsible
for specific binding of the a-ammonium group of trimethyllysine
(Asp131 in TMLH, Asn191 in BBOX).5
In contrast to recent structural, mechanistic and inhibition
studies on BBOX,5–13 little is known about the mechanism
and substrate requirements for TMLH catalysis. Early work
on cellular TMLH, based on column chromatography, radio-
active labelling, oxidative cleavage reactions and limited NMR
analyses, provided basic evidence that the enzyme catalyses
the C-3 hydroxylation of trimethyllysine and highlighted that
trimethyllysine is a natural substrate.14–17 Previous biochemical
studies, however, did not provide any insight into whether TMLH
also has a potential to catalyse the hydroxylation of other natural
and unnatural trimethyllysine analogues. Herein, we report
the examination of trimethyllysine analogues as substrates for
TMLH, employing the MS and NMR-based assays.
A recently developed protocol for the eﬃcient bacterial produc-
tion of stable and active human TMLH-a isoform as the MBP-
TMLH fusion protein prompted us to explore its substrate scope.18
We first tested L-trimethyllysine as a substrate for the recombi-
nantly expressed MBP-TMLH-a (hereafter referred to TMLH) using
the highly sensitive MS and information rich NMR assays. The
incubation of trimethyllysine (500 mM) in the presence of TMLH
(3 mM), FeSO4, 2OG and ascorbate at 37 1C for 30 minutes
resulted in almost quantitative production of 3-hydroxy-L-trimethyl-
lysine (90% by MS and 81% by 1H NMR) as indicated by the
mass shift of +16 Da by MS (Fig. S1, ESI†), and the integration
Fig. 1 The carnitine biosynthesis.
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of NMe3
+ peaks of the trimethyllysine starting material and the
3-hydroxy-L-trimethyllysine product by 1H NMR (Fig. 2A).
1H NMR data and more detailed 2D NMR analyses provided
unambiguous evidence that the enzymatic hydroxylation occurs
at the C-3 site (Fig. 2 and Fig. S2, S3, ESI†). The 1H–1H COSY
spectrum revealed that the new downfield resonances at 4.07
and 3.78 ppm are coupled to each other (Fig. 2B), and sub-
sequent analysis of the TOCSY spectrum revealed a coupling
network consistent with a trimethyllysine derivative (Fig. S2
and S3, ESI†). The multiplicity-edited 1H–13C HSQC spectrum
confirmed that these resonances were methines (as opposed
to methylenes) with 13C chemical shifts consistent with a Ca
(59.3 ppm) carbon and a secondary alcohol (Cb, 68.8 ppm)
carbon (Fig. 2C). Our advanced NMR analyses, however, were
not able to conclusively assign the stereochemistry at the C-3,
presumably due to freely rotatable Ca–Cb bond. Based on the
results from previous studies, the absolute configuration at the
C-3 has not been unquestionably established, although it has
been suggested that 3-hydroxy-L-trimethyllysine possesses the
2S, 3S stereochemistry (i.e. the erythro form).15 It is envisioned
that the further work using the synthetic enantiopure (3S)- and
(3R)-3-hydroxy-L-trimethyllysine, will provide the unambiguous
confirmation of the exact stereochemistry of the TMLH-catalysed
formation of the 3-hydroxy-L-trimethyllysine product. Our
NMR analyses, however, revealed that the TMLH-catalysed C-3
hydroxylation of trimethyllysine is tightly coupled to the conversion
of 2OG to succinate (the ratio succinate formation :hydroxylation
was observed to be 1.1). This result is in agreement with mecha-
nistic studies on other non-haem Fe(II) and 2OG oxygenases,
including BBOX.5,7,9
Control experiments under standard conditions, but in the
absence of TMLH, showed no formation of 3-hydroxytrimethyl-
lysine, indicating that the hydroxylation is TMLH-catalysed
(Fig. S4, ESI†). MS and NMR analyses, furthermore, illustrated
that the presence of Fe(II), 2OG and ascorbate, respectively, is
required for the eﬃcient enzymatic hydroxylation of trimethyl-
lysine (Fig. S5–S7, ESI†). These results are in line with previous
biochemical studies on mitochondrial TMLH extracts.14,16
We also carried out the enzymatic assay in H2
18O (90% 18O,
phosphate buﬀer, pH 7.0) under standard conditions. MS analyses
showed that 18O was not incorporated in 3-hydroxytrimethyllysine
product, implying that the oxygen atom in 3-hydroxytrimethyllysine
derives from molecular oxygen, and not from water (Fig. S8,
ESI†). This result is consistent with the catalytic cycle and the
oxygen labelling studies on several other members of Fe(II)/2OG
oxygenases.7,19
Although there is some evidence that trimethyllysine that is
required for carnitine biosynthesis in mammals can be obtained
via food (e.g. vegetables),20 the most likely source of trimethyllysine
in cells are endogeneous trimethyllysine-containing proteins, most
commonly histones, calmodulin, cytochrome C and myosine.21
We have tested physiologically important and abundant histones
H3K4me3 and H3K9me3 as potential substrates for TMLH. Our
MALDI-TOF MS analyses showed that H3K4me3 and H3K9me3
histone peptides are not hydroxylated in the presence of TMLH
under standard conditions (Fig. S9, ESI†). These results on repre-
sentative trimethyllysine-containing proteins/peptides suggest that
it is unlikely that 3-hydroxytrimethyllysine could also be obtained
via TMLH-catalysed C-3 hydroxylation of trimethyllysine that is
present in various proteins, followed by the proteolytic degradation
of such hydroxylated proteins.
After verifying that trimethyllysine, in its free form, is an
excellent substrate for TMLH, we examined other naturally occur-
ring lysine derivatives (Fig. 3). Dimethyllysine (2) was observed to
be a poor substrate for TMLH, yielding only a small amount (25%
conversion) of hydroxylated product by MS assay, and only traces
of the product were detected by NMR (Fig. S10, ESI†). Methyllysine
(3) and lysine (4) were not hydroxylated in the presence of TMLH
under standard conditions (Fig. S11 and S12, ESI†), even after
prolonged incubation (2 hours), highlighting that the presence
of methyl groups on the e-N site of lysine has a profound eﬀect
on substrate eﬃciency, presumably via the contribution of the
energetically favourable cation–p interactions.
In contrast to L-trimethyllysine, its enantiomer D-trimethyllysine
(5) did not undergo TMLH-catalysed hydroxylation reaction, as
indicated by MS and NMR analyses (Fig. 3 and Fig. S13, ESI†).
We did not observe any 3-hydroxy-D-trimethyllysine, nor the
TMLH-mediated conversion of 2OG to succinate. It is indeed
interesting that the stereochemistry on C-2 (i.e. the a carbon)
fully determines the substrate eﬃciency.
We then carried out structure–activity relationship studies
with the aim of determining which other features of L-trimethyl-
lysine are responsible for its ability to act as a specific substrate
for TMLH. 5-Trimethylamino-1-aminopentane (6), which does
not possess the C-1 carboxylate functionality, was not hydroxy-
lated in the presence of TMLH (Fig. 3 and Fig. S14, ESI†).
Fig. 2 NMR analyses of TMLH-catalysed C-3 hydroxylation of trimethyl-
lysine. (A) 1H NMR data and the assignment of 3-hydroxytrimethyllysine.
(B) COSY data showing the Ha–Hb coupling. (C) HSQC data showing the
Ca–Ha and Cb–Hb couplings. (asc. = ascorbate).
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Similarly, the methyl ester of trimethyllysine (7) was found not
to be a TMLH substrate (Fig. 3 and Fig. S15, ESI†). These two
analogues showcase that the negatively charged C-1 carboxylate
moiety of trimethyllysine is required for productive enzymatic
hydroxylation. We also investigated whether the a-ammonium
group of trimethyllysine contributes to substrate recognition.
The absence of the a-ammonium group (as in 6-trimethyl-
aminohexanoic acid, 8) resulted in an inactive substrate (Fig. 3
and Fig. S16, ESI†). In addition, the positively charged and
bulkier hexamethyllysine (9) and the neutral N-acetyltrimethyl-
lysine (10) were observed not to be substrates for TMLH in our
assays (Fig. 3 and Fig. S17, S18, ESI†). These results illustrate the
essential role of the free a-ammonium group, possibly via the
formation of the energetically favourable salt bridge with Asp131
of TMLH. Our NMR work also showed that none of trimethyl-
lysine analogues that have altered a-ammonium or C-1 carboxylate
functionalities stimulated TMLH-mediated uncoupled turnover
of 2OG to succinate.
The eﬀect of the chain length on the substrate eﬃciency was
also investigated. Trimethylornithine (11), a one methylene
shorter analogue of trimethyllysine, underwent TMLH-catalysed
C-3 hydroxylation (75% conversion) under standard assay con-
ditions (Fig. 4 and Fig. S19–S21, ESI†). The removal of two
methylene groups (as in trimethyldiaminobutyric acid, 12),
however, led to no observed hydroxylation by MS and NMR
(Fig. 3 and Fig. S22, ESI†). Longer trimethylhomolysine (13) was
found to be a good TMLH substrate (70% conversion, Fig. S23,
ESI†), but comparatively worse than trimethyllysine. Out of two
potential hydroxylation sites (C-3 and C-4), the hydroxylation of
13 exclusively occurs at the C-3 site; we could not assign the
stereochemistry at C-3 due to rotatable Ca–Cb single bond
(Fig. 4 and Fig. S24, S25, ESI†). Collectively, these results show
that TMLH has the ability to catalyse the hydroxylation of
unactivated C–H bonds in slightly shorter or longer trimethyl-
lysine analogues, suggesting that there is some structural
flexibility that enables the enzymatically productive recognition
processes; similar trends were observed for BBOX-catalysed
hydroxylation of g-butyrobetaine and its simplest analogues.5,9
In contrast to the natural metabolite 3-hydroxy-L-trimethyllyine,
hydroxylated trimethylornithine and trimethylhomolysine pro-
ducts have not yet been found in natural sources. The observation
that TMLH catalyses the C-3 hydroxylation of trimethylornithine
might be biologically relevant, as trimethylornithine-containing
lipids have been characterised in Planctomycetes.22
Having shown that TMLH has the ability to accept one
methylene shorter and longer analogues of trimethyllysine, we
next investigated whether TMLH catalyses the hydroxylation of
trimethyllysine analogues that bear bulkier trialkylammonium
functionality. Dimethylethyllysine (14), dimethylpropyllysine (15),
and dimethylisopropyllysine (16) were all eﬃciently hydroxylated
in the presence of TMLH under standard conditions (Fig. 4 and
Fig. S26–S34, ESI†). 2D NMR analyses revealed that, as in the case
of trimethyllysine, these three substrates are hydroxylated at the
C-3 site (none of the three hydroxylated products has been
previously (bio)synthesised). NMR experiments confirmed that
the enzymatic hydroxylation is well coupled to the conversion of
2OG to succinate. A sterically more demanding triethyllysine (17)
was found to be a very poor substrate (traces detected) for TMLH
by MS, whereas we could not detect the hydroxylated product by
NMR (Fig. 3 and Fig. S35, ESI†). These results suggest that the
putative aromatic cage of TMLH, comprised of Tyr217, Trp221
and Tyr234, is arranged in the way that allows binding of
Fig. 3 Trimethyllysine analogues that are not substrates for TMLH. 2 was
observed to be a poor TMLH substrate by MS and NMR analyses.
Fig. 4 TMLH-catalysed hydroxylation of trimethyllysine analogues.
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alkylated dimethyllysines, whereas it does not accept significantly
bulkier trimethyllysine analogues. In this regard, inhibition
studies on the related BBOX showed that its aromatic cage also
poses constraints on substrates that bear bulkier trialkyl-
ammonium groups, but not on the alkyldimethyl derivatives
of g-butyrobetaine.12
Naturally occurring symmetric and asymmetric dimethyl-
arginines (18 and 19) are produced by proteolytic degradation
of methylated proteins.23 Dimethylated arginines possess both
a fixed positive charge and hydrophobic methyl groups at the
end of the side chain; these features are similar to those of
trimethyllysine, although the geometry and the chain length
diﬀer. Despite the chemical similarities with trimethyllysine,
dimethylated arginines were found not to be substrates for
TMLH in our MS and NMR assays (Fig. 3 and Fig. S36, S37,
ESI†). It is possible that the planar guanidinium group of
dimethylarginine exhibits a geometry and size that prevents
an eﬃcient association with the aromatic cage of TMLH.
Targeting carnitine biosynthesis by small molecules has been
recognised as a promising strategy for treatment of cardiovascular
diseases. Mildronate (also known as meldonium, 20) is a clinically
used g-butyrobetaine competitive and specific BBOX inhibitor
that undergoes the unusual Steven’s-type rearrangement.6,24 Our
MS and NMR studies revealed that mildronate is neither a
substrate (at 500 mM) nor inhibitor (at 1 mM) of TMLH under
standard conditions (Fig. 3 and Fig. S38, S39, ESI†). These data
indicate that, out of the two Fe(II)/2OG oxygenases involved in
carnitine biosynthesis, mildronate only acts as an inhibitor of
BBOX (Fig. 1). In line with these results, our studies showcase that
g-butyrobetaine (21), the natural substrate for BBOX, does not
undergo TMLH-catalysed hydroxylation to yield L-carnitine (Fig. 1,
3 and Fig. S40, ESI†). The work on TMLH reported here, together
with recent studies on BBOX,5,9 demonstrate that TMLH and
BBOX are highly specific enzymes that only catalyse hydroxylation
of carnitine biosynthesis intermediates L-trimethyllysine and
g-butyrobetaine, respectively.
In conclusion, we have demonstrated that TMLH has the ability
to catalyse the hydroxylation of an unactivated C–H bond in several
trimethyllysine analogues. Our structure–activity relationship
studies highlight the essential contributions from various
structural elements of trimethyllysine that are required for
efficient substrate hydroxylation. This study raises the possibility
that the engineered TMLHs could be used as biocatalysts for
the hydroxylation of structurally diverse unnatural amino acids.
This work, furthermore, spotlights the opportunities in drug
discovery by targeting carnitine biosynthesis via TMLH inhibition.
We thank Dr Andris Kazaks (Latvian Biomedical Research
and Study Centre) for kindly providing the MBP-TMLH plasmid.
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